08 January 2020
Visiongain’s new report the In Vitro Diagnostics Quality Control Market Report : Forecasts by Type (Quality Control, Quality Assurance Services, Data Management Solutions), by Application (Immunochemistry, Hematology, Clinical chemistry, Molecular Diagnostics, Coagulation, Others), by End User (Hospitals, Home Care, Others), plus analysis of leading companies operating in the global In Vitro Diagnostics Quality Control market.
The rising number of accredited clinical laboratories, increasing third-party quality control services, and the strong presence of favorable regulatory bodies to drive global In Vitro Diagnostics Quality Control market over the projected period. In 2019, the global In Vitro Diagnostics Quality Control market was valued at $1.05 billion and is expected to reach $1.61 billion by 2029 at a CAGR of 4.4%. However, the unfavorable scenario of reimbursement in the IVD industry followed by the high cost of IVD quality control services is expected to hinder market growth over the coming years.
Increasing penetration of diagnostic laboratories by virtue of rising prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, and infectious diseases. Rising prevalence of chronic diseases in developed as well as developing economies to encourage global In Vitro Diagnostics Quality Control industry over the coming years.
Strong regulatory bodies associated with the regular quality check of IVD instruments and monitoring of quality control are expected to strengthen the industry. Some prominent bodies are U.S. The Food and Drug Administration, Central Drug Standard Control Organization (CDSCO), Ministry of Health, Labor & Welfare (MHLW), Ministry of Health for South Africa, Medicines and Healthcare Products Regulatory Agency (MHRA), Health Canada, Therapeutic Goods Administration (TGA), and European Medicines Agency.
List of prominent players operating in global In Vitro Diagnostics Quality Control industry are Siemens Healthcare, Abbott Diagnostics, Inc, Bio-Rad Laboratories, Inc., Danaher Corporation, Roche Diagnostics, Sysmex Corporation, Sero AS, Thermo Fisher Scientific, Inc, Sun Diagnostics, LLC, Ortho Clinical Diagnostics, Inc., Randox Laboratories Ltd, Helena Laboratories Corporation, SeraCare Life Sciences, Inc, and Technopath Clinical Diagnostics.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market is expected to be driven by key factors such as rising cancer prevalence, government funding support in genetic research and technological advancements taking place in the biological research field. In addition, the market is predicted to gain huge traction in the developing countries.
11 May 2021
Strong product portfolio in the market is one of the major factors accelerating the growth of the market as availability of variants in the single-use systems allows targeted users more options.
11 May 2021
The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.
06 May 2021
Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.